Companies › Gedeon Richter
1 active drug program in 3 registered trials: 2 Phase 4, 1 Phase 3; Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 3 | Schizophrenia; Depression, Bipolar; Bipolar I Disorder | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03817502 | Cariprazine | Phase 3 | Schizophrenia | Psychiatry | Dec 2026 |
| NCT05913947 | Cariprazine | Phase 4 | Depression, Bipolar | Psychiatry | Sep 2028 |
| NCT06433635 | Cariprazine | Phase 4 | Bipolar I Disorder | Psychiatry | Feb 2030 |
LB Pharmaceuticals Reviva Pharmaceuticals Cybin IRL Beijing Union Pharmaceutical Factory Newron Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.